拜耳完成对Perfuse Therapeutics的收购-动脉网

Bayer completes acquisition of Perfuse Therapeutics

拜耳等信源发布 2026-06-17 14:32



可切换为仅中文







June

六月

2026

08:30 AM

上午 08:30

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer completes acquisition of Perfuse Therapeutics

拜耳完成对Perfuse Therapeutics的收购

Not intended for UK Media

非面向英国媒体

Berlin, Germany, June 17, 2026

2026年6月17日，德国柏林

–

Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As

拜耳今日宣布完成对 Perfuse Therapeutics, Inc. 的收购。因此，Perfuse Therapeutics 现已完全整合进拜耳。

announced previously

此前宣布

, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR).

，拜耳现在拥有与PER-001玻璃体内植入物相关的全部权利，这是一种首创的、缓释小分子内皮素受体拮抗剂，目前正处于治疗青光眼和糖尿病视网膜病变（DR）的第二期临床开发阶段。

This acquisition strengthens Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s strong footprint and expertise in ophthalmology.

此次收购增强了拜耳的医药产品管线，并与拜耳在眼科领域的强大布局和专业知识战略契合。

Under the terms of the agreement, Bayer paid an upfront payment of USD 300 million. The transaction carries a total potential value of up to USD 2.45 billion, comprising of the upfront payment and additional success-based milestone payments.

根据协议条款，拜耳支付了3亿美元的首付款。该交易的总潜在价值高达24.5亿美元，包括首付款和额外的基于成功条件的里程碑付款。

For Bayer, BofA Securities acted as exclusive financial advisor and Baker McKenzie acted as legal counsel. For Perfuse, Centerview Partners LLC acted as exclusive financial advisor and Goodwin Procter LLP acted as legal counsel.

就拜耳而言，美银证券担任独家财务顾问，贝克·麦坚时律师事务所担任法律顾问。就Perfuse而言，Centerview Partners LLC担任独家财务顾问，古德温·普罗克特律师事务所担任法律顾问。

About Perfuse Therapeutics

关于 Perfuse Therapeutics

Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness.

Perfuse Therapeutics 是一家生物制药公司，致力于开创性研究缺血性眼病的治疗方法。凭借其专有的缓释药物递送平台，该公司正在推进其核心资产 PER-001，以应对全球主要的致盲原因。

Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world..

Perfuse Therapeutics 总部位于加利福尼亚州南旧金山，并在北卡罗来纳州达勒姆设有研发设施，已组建一支强大的团队，致力于为全球眼病患者推进疾病修饰疗法。

About Bayer'

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域拥有核心竞争力的全球性企业。秉承“人人享有健康，无人遭受饥饿”的使命，公司的产品和服务旨在通过支持应对全球人口增长和老龄化所带来的重大挑战，帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros.

拜耳致力于推动可持续发展，并通过其业务产生积极影响。同时，集团旨在通过创新和增长提升盈利能力并创造价值。拜耳品牌在全球范围内代表着信任、可靠和品质。在2025财年，集团员工人数约为88,000人，销售额达456亿欧元。

R&D expenses amounted to 5.8 billion euros. For more information, go to .

研发费用达58亿欧元。更多信息，请访问。

www.bayer.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com/

在 Facebook 上关注我们：

http://www.facebook.com/bayer

Forward-Looking Statements

前瞻性陈述

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本新闻稿可能包含基于拜耳管理层当前假设和预测的前瞻性陈述。各种已知和未知的风险、不确定性和其他因素可能导致公司未来的实际业绩、财务状况、发展或表现与本文给出的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳在其公开报告中讨论的因素，相关报告可在拜耳网站获取。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

. 本公司概不承担更新这些前瞻性陈述或使其与未来事件或发展保持一致的任何责任。

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

拜耳股份公司是一家在全球拥有运营子公司的控股公司。本文中提及的“拜耳”或“本公司”可能根据上下文需要指代一家或多家子公司。

Contact for media inquiries:

媒体垂询联系人：

Lisa Varrelmann, phone: +49 1746466492

丽莎·瓦雷尔曼，电话：+49 1746466492

Email:

电子邮件：

lisa.varrelmann@bayer.com

Contact for investor inquiries:'

投资者咨询联系方式：

Bayer Investor Relations Team, phone +49 214 30-72704

拜耳投资者关系团队，电话 +49 214 30-72704